Key Highlights
- Truenat HR‑HPV‑Plus, developed by Molbio Diagnostics, is the first Indian point‑of‑care HPV assay to meet WHO‑IARC validation criteria.
- The assay detects eight high‑risk HPV genotypes responsible for roughly 95% of cervical cancers and can be deployed at district‑level health centres.
- Screening remains essential for women over 30, even after mass vaccination, because HPV infection persists as the main driver of cervical malignancy.
- The validation study involved 1,159 cervical specimens, demonstrating accuracy comparable to established international platforms.
- Local production eliminates dependence on costly imports, lowering test costs and expanding reach to underserved rural populations.
Detailed Insights
Researchers from AIIMS New Delhi, in collaboration with ICMR laboratories and the WHO‑affiliated International Agency for Research on Cancer (IARC) in France, rigorously evaluated four domestically‑designed HPV DNA kits. Only the Truenat HR‑HPV‑Plus satisfied every benchmark set by the WHO/IARC validation protocol, including sensitivity, specificity, and reproducibility across multiple laboratories.
The study, funded by the Department of Biotechnology’s BIRAC under the Grand Challenges India programme, analysed 1,159 cervical samples that comprised confirmed precancerous lesions and invasive cancer cases. While another indigenous kit, Pathodetect‑7 from MyLabs, exhibited respectable sensitivity, it fell short of the full validation suite.
Vaccination campaigns drastically reduce new HPV infections but do not eradicate risk for women already in the high‑risk age bracket (30 years and above). Consequently, widespread, affordable screening is indispensable for achieving the national goal of cervical‑cancer elimination. The Truenat platform’s existing footprint in peripheral health facilities accelerates roll‑out, as staff are already trained on its operation.
Key Concepts
- HPV (Human Papillomavirus): A sexually transmitted virus with certain high‑risk strains that can initiate cervical cellular transformation.
- Point‑of‑Care Test: A diagnostic assay designed for use at or near the patient’s location, requiring minimal infrastructure.
- WHO‑IARC Validation: An internationally recognised evaluation framework that measures a test’s diagnostic performance against gold‑standard criteria.
- High‑Risk HPV Types: The eight genotypes most frequently linked to cervical cancer, accounting for the majority of disease burden.
- Screen‑and‑Treat Strategy: A public‑health approach that couples early detection with prompt therapeutic intervention to halt disease progression.